Fig. 5From: Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trialCumulative incidence of overall chronic graft-versus-host disease (cGVHD) (A) and severe cGVHD (B). A, B Stratified according to whether patients receiving MSCs post-randomization. *P < 0.05, **P < 0.001Back to article page